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ABSTRACT  
Patients with diabetes tend to have an increased risk of osteoporosis that may be related to 
hyperglycemia. In vitro evidence has shown that high glucose can affect the proliferation and 
osteogenic differentiation of mesenchymal stem cells (MSCs). Tissue regeneration depends 
mainly on MSCs. However, the exact mechanisms involved in high glucose–induced bone 
loss remain unknown. In this study, we investigated the effects of high glucose on the prolif-
eration and osteogenic differentiation of mice bone MSCs (BMSCs) and determined the spe-
cific mechanism of bone morphogenetic protein 2 (BMP-2) in the osteogenic differentiation 
of mice BMSCs in a high-glucose microenvironment. High glucose (< 25 mM) promoted cell 
growth but suppressed mineralization. The intracellular BMP-2 level in BMSCs cultured in a 
high-glucose microenvironment was significantly decreased and suppressed activation of the 
BMP signaling pathway. Consequently, expression of the osteogenic markers Runx2, alkaline 
phosphatase, and osteocalcin were decreased. Meanwhile, supplementation with ectogenic 
BMP-2 reversed the cell osteogenic differentiation and osteogenic marker down-regulation 
under high glucose. Our data indicate that BMP-2 plays an important role in regulating the 
osteogenic differentiation of BMSCs in a high-glucose microenvironment. Thus, it is possible 
that agents modifying this pathway could be used by BMSCs to promote bone regeneration in 
high-glucose microenvironments. 
 
Keywords: Bone mesenchymal stem cells, molecular pathways, high glucose, osteogenic dif-
ferentiation, BMP-2  
 
 
INTRODUCTION 
Diabetes mellitus, a metabolic disease 
characterized by hyperglycemia, can cause 
disorder of bone metabolism, leading to 
bone loss or osteoporosis, a bone condition 
defined by low bone mass and decreased 
bone quality (Duarte et al., 2005; Schwartz, 
2003). Moreover, diabetes is one of the risk 
factors that causes periodontal disease and 
alveolar bone loss (Al-Emadi et al., 2006). 
Javed and Romanos (2009) reported that 
poorly controlled diabetes negatively af-
fected implant osseointegration, but osse-
ointegration could successfully take place 
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in patients with diabetes under optimal se-
rum glycemic control, and animal studies 
have confirmed this premise (de Molon et 
al., 2013). It is well known that hypergly-
cemia is a major cause of complications of 
diabetes and that maintaining blood glucose 
at a level as close to normal as possible is 
the main treatment aim, which can restore 
decreased bone mineral density in diabetic 
patients (Krakauer et al., 1995). In a strep-
tozotocin-induced mouse model of insulin-
dependent diabetes mellitus, Botolin and 
McCabe (2006) demonstrated that diabetes-
associated hyperglycemia modulated osteo-
blast gene expression, function, and bone 
formation and thereby caused diabetic bone 
loss. However, the exact mechanism of how 
high glucose induces bone loss remains un-
clear. 
Mesenchymal stem cells (MSCs), 
commonly isolated from adult bone mar-
row, have the potential to undergo multilin-
eage differentiation into multiple connec-
tive tissue cell types, such as osteoblasts, 
chondrocytes, adipocytes, and myoblasts 
(Tuli et al., 2003). Bone MSCs (BMSCs) 
are an excellent source of proliferative os-
teoprogenitor cells that can be induced to 
differentiate into osteoblasts (Porter et al., 
2003; Walsh et al., 2001). During develop-
ment, osteoprogenitors pass through a se-
ries of complicated stages, including prolif-
eration, differentiation, matrix deposition, 
and matrix mineralization, and eventually 
become mature osteoblasts. This process 
can be affected by the microenvironment. 
Liu et al. (2011) found that an inflammato-
ry microenvironment inhibited osteogenic 
differentiation potential but promoted the 
proliferation of periodontal ligament stem 
cells through the activation of β-catenin, 
which suppressed the non-canonical Wnt/ 
Ca2+ pathway. Gopalakrishnan et al. (2006) 
found that high concentrations of glucose 
inhibited BMSC proliferation, alkaline 
phosphatase (ALP) activity, collagen for-
mation, and mineralization. Wang et al. 
(2010) noted that high glucose inhibited 
osteogenic differentiation and increased ad-
ipogenic differentiation by activating the 
cAMP/ PKA/ERK pathway in MG-63 cells. 
In our previous study, we found that high 
glucose interfered with the proliferation and 
differentiation of rat mandible osteoblasts 
(Ma et al., 2011). However, the mechanism 
by which high glucose affects BMSC oste-
ogenic differentiation has not been clari-
fied. 
In this study, we exposed mice BMSCs 
to medium containing different concentra-
tions of glucose to test the hypothesis that 
high glucose stimulates BMSC proliferation 
but inhibits their osteogenic differentiation. 
We found that a high glucose concentration 
(< 25 mM) stimulated BMSC proliferation 
but inhibited osteogenic differentiation in a 
dose-dependent manner. Furthermore, our 
data demonstrated that bone morphogenetic 
protein 2 (BMP-2) expression was de-
creased by high glucose, accompanied by a 
decreased expression of Runx2, and this 
inhibition effect could be reversed with ad-
ditional ectogenic BMP-2. Our finding sug-
gests that high glucose suppresses BMSC 
osteogenic differentiation though the BMP 
signaling pathway, which may be helpful to 
improve the osseointegration of alevolar 
bone implants in patients with diabetes. 
 
MATERIALS AND METHODS 
Cell culture 
A frozen vial of murine BMSCs (isolat-
ed from 4-5-week-old female C57/BL6 
mice; Cyagen Biosciences, Guangzhou, 
China) was thawed and expanded according 
to the supplier instructions. The BMSCs 
used in all experiments were passage 4 
cells. 
 
Cell growth assay 
Cells were plated at a density of 5 × 103 
cells/well in 96-well plates for 24 h, and 
then treated with Dulbecco’s modified Ea-
gle’s medium (DMEM; Invitrogen Gibco 
Rockville,MD, USA)) containing normal 
(5.5 mM) or high glucose (16.5 mM, 25 
mM, and 35 mM) concentrations. The MTT 
assay was carried out for nine days accord-
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ing to the cell proliferation kit protocol 
(Sigma, St. Louis, MO/USA). Absorbance 
was determined at 490 nm with a micro-
plate reader (Bio-Tek Instruments, Winoo-
ski, VT, USA). All reported values are pre-
sented as the means of triplicate samples. 
This test was repeated three times. 
 
Flow cytometric analysis 
Cells were plated at a density of 3 × 105 
cells/well in 6-well plates and cultured until 
80 % confluence. The cells were starved 
using a serum-free medium containing 1% 
fetal bovine serum (FBS; Invitrogen Gibco) 
for 24 h, and then treated with DMEM (plus 
10% FBS) containing normal (5.5 mM) or 
high glucose (16.5 mM, 25 mM, and 
35 mM) concentrations, respectively. Flow 
cytometry analysis was performed at day 5. 
The fractions of cells in the G0/G1, G2, and 
S phases of the cell cycle were analyzed 
and the proliferation index was determined 
(Zheng et al., 2009).  
The apoptotic cells were measured us-
ing annexin V-FITC conjugated to propidi-
um iodide (PI) by flow cytometry. On cul-
ture day seven, the harvested cells were as-
sayed for apoptosis using an annexin V-
FITC apoptosis detection kit (Becton Dick-
inson Bioscience, San Jose, CA, USA) ac-
cording to the manufacturer instructions 
(Velagapudi et al., 2011). Briefly, the cells 
were treated as described above, and then 
gently washed twice with annexin-binding 
buffer, detached from the plate using 0.05% 
trypsin (Sigma), suspended in cold binding 
buffer, and stained with annexin V-FITC 
and PI. Analysis was conducted for 2 × 104 
cells using a flow cytometer with CellQuest 
software (Becton-Dickinson, Rutherford, 
NJ, USA) using FL1 and FL2 ranges for 
annexin V-FITC and PI, respectively. An-
nexin V-FITC–positive, PI-negative cells 
were scored as apoptotic. Double-stained 
cells were considered either necrotic or late 
apoptotic. 
 
Mineralization assay 
Osteogenic differentiation of the stem 
cells was performed as previously described 
(Pittenger et al., 1999). Briefly, 3 × 105 
BMSCs/well were plated in a 6-well plate 
and cultured in DMEM supplemented with 
10% FBS until confluent. Then, the medi-
um was changed to DMEM with 1% FBS 
for 24 h to starve the cells. Subsequently, 
the cells were incubated with osteogenic 
DMEM (100 nM dexamethasone, 50 μg/mL 
ascorbic acid, and 5 mM β-glycerophospha-
te; Sigma) for another 21 d. The medium 
contained 5.5, 16.5, 25, and 35 mM gluco-
se, respectively. The medium was changed 
every 3-4 d. The cells were then fixed with 
75% ethanol and stained with 2% Alizarin 
red S (Sigma). To quantify the Alizarin red 
S–stained nodules, the stain was solubilized 
with 0.5 mL 5% sodium dodecyl sulfate 
(SDS) in 0.5 N HCl for 30 min at room 
temperature. The solubilized stain 
(0.15 mL) was transferred to a 96-well 
plate, and the absorbance was measured at 
405 nm. 
 
Western blot analysis 
3 × 105 BMSCs/well were plated in two 
6-well dishes until confluent, divided into 
four groups, and incubated with osteogenic 
medium containing 5.5 or 25 mM glucose 
or DMEM containing 5.5 or 25 mM glu-
cose (control). After seven days of culture, 
whole cell lysates were extracted with lysis 
buffer (10 mM Tris-HCl, 1 mM EDTA, 1% 
SDS, 1% Nonidet P-40, 1:100 proteinase 
inhibitor cocktail, 50 mM β-glycerophos-
phate, 50 mM sodium fluoride) for western 
blotting. The protein content of the lysate 
was determined using a protein assay kit 
(Beyotime) following the manufacturer’s 
recommended protocol. The proteins were 
loaded on 8% SDS polyacrylamide gels, 
transferred to PVDF membranes (Millipore, 
Billerica, MA, USA) and blocked with 5% 
nonfat milk powder in PBST (phosphate-
buffered saline with 0.1% Tween). The 
membranes were probed overnight with the 
following monoclonal primary antibodies: 
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anti–BMP-2 (Abcam, Cambridge, UK) and 
anti–β-actin (Cell Signaling Technology, 
Beverly, MA, USA). The membranes were 
then incubated with anti-mouse horseradish 
peroxidase-conjugated secondary antibody 
(Boster, Wuhan, China). The blots were 
visualized using an enhanced chemilumi-
nescence kit (Amersham Biosciences, Pis-
cataway, NJ, USA) according to the manu-
facturer’s recommended instructions.  
 
ALP activity analysis 
The ALP activity assay was performed 
with an ALP kit according to the manufac-
turer protocol (Jiancheng, Nanjing, China). 
Seven days after osteogenic induction, the 
cells were fixed with 70% ethanol and in-
cubated with a solution of 0.25% naphthol 
AS-BI phosphate and 0.75% Fast Blue BB 
dissolved in 0.1 M Tris buffer (pH 9.3) for 
ALP staining. This test was repeated three 
times. 
 
Quantitative real-time polymerase chain 
reaction  
Cells were cultured and divided into 
four groups as above. Total RNA was iso-
lated using TRIzol (Invitrogen) at day sev-
en. Approximately 2–5 µg total RNA from 
each group was converted to cDNA with a 
SuperScript First-Strand Synthesis kit (Invi-
trogen). The quantitative real-time poly-
merase chain reaction (qRT-PCR) was per-
formed using a QuantiTect SYBR Green 
PCR kit (Toyobo, Osaka, Japan) and the 
Applied Biosystems 7500 Real-time PCR 
Detection System (Applied Biosystems, 
Foster City, CA, USA). Two independent 
experiments were performed for each reac-
tion in triplicate. The primers used are 
listed in Table 1. 
 
BMP-2 treatment 
The cells were plated in 6-well dishes, 
and cultured and grouped as above. The 
cells were then treated with or without (as 
control) 100 ng/mL BMP-2 (Wyeth Re-
search Genetics Institute) (Pountos et al., 
2010). On culture day seven, the cells were 
harvested and assayed for osteogenic dif-
ferentiation. Whole-cell lysates were ex-
tracted with lysis buffer for western blot 
analysis to verify the BMP-2 content. Total 
RNA was isolated from eight groups and 
qRT-PCR was utilized to test the expres-
sion of RUNX2, ALP, and osteocalcin 
(OCN) mRNA.  
 
Statistical analysis 
The data were subjected to an inde-
pendent samples t-test or one-way ANOVA 
using SPSS. The results are expressed as 
mean ± SD. For all analyses, P < 0.05 was 
used to indicate statistical significance. 
 
RESULTS 
High-glucose microenvironment inter-
fered with BMSC proliferation and osteo-
genic differentiation  
As the osteogenic differentiation of 
MSCs would be affected by their microen-
vironment, we systematically explored the 
biological function of mouse BMSCs in a 
high-glucose microenvironment. We used 
four different glucose concentrations (5.5, 
16.5, 25, and 35 mM) in our study.  
It was demonstrated that, based on the 
glucose content, high glucose had a contra-
ry effect on BMSC proliferation. From day 
five, the growth of BMSCs cultured in 
DMEM containing 25 mM glucose was bet-
ter than that of BMSCs cultured in DMEM 
containing 5.5 mM glucose (P < 0.05). 
From day seven, DMEM containing 16.5 
and 25 mM glucose both promoted BMSC 
proliferation. Furthermore, the medium 
containing 25 mM glucose exerted the best 
effects on BMSC proliferation in the four 
groups (P < 0.05). The medium containing 
35 mM glucose had a notable effect on 
BMSC proliferation. Initially, it promoted 
BMSC proliferation; at day three, it was 
evident that BMSCs cultured in the DMEM 
containing 35 mM glucose had the best 
growth compared to the other three groups 
(P < 0.05). However, the BMSC prolifera-
tion deteriorated and had worse growth than 
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the other three groups after three days 
(P < 0.05; Figure 1A). The flow cytometric 
analysis showed that the BMSC prolifera-
tion indices were as follows: 25 mM group 
> 16.5 mM group > 5.5 mM group > 35 
mM group (P < 0.05; Table 2; Figure 1B, 
1D). The annexin V-FITC/PI quantification 
assay demonstrated that the number of 
apoptotic cells cultured in DMEM contain-
ing 35 mM glucose was much greater (ap-
proximately 31.28 %) than that of the other 
three groups (< 16 %, P < 0.05; Figure 1C, 
1E). 
The Alizarin red S staining showed that 
the mineralization of BMSCs was inhibited 
by high glucose (16.5 - 35 mM) on day 21 
(Figure 2A). Inverted microscopy revealed 
that the number and size of mineral nodules 
decreased as the glucose concentration in-
creased. It was extremely difficult to detect 
typical mineral nodules in the BMSCs 
grown in medium containing 35 mM glu-
cose. The optical density values from the 
Alizarin red S staining quantification were 
0.440, 0.303, 0.262, and 0.113 in 5.5 mM, 
16.5 mM, 25 mM, and 35 mM glucose, re-
spectively, indicating a negative relation-
ship between osteogenic ability and high 
glucose concentration (P < 0.01; Figure 
2B). Based on the effects of high glucose 
on the proliferation and osteogenic differen-
tiation of the BMSCs, we selected 5.5 mM 
glucose as the normal group (control) and 
25 mM glucose as the high-glucose group 
for further experiments.  
 
High glucose inhibited BMP-2 activity 
Recent studies have demonstrated that 
the BMP pathway appears to play an im-
portant role in MSC osteogenic differentia-
tion (Lin and Hankenson, 2011) and BMP-
2, which is a key protein of the BMP sig-
naling pathway, was altered in high-glucose 
conditions (Chen et al., 2006). Thus, we 
postulated that the high-glucose microenvi-
ronment would inhibit the BMP signaling 
pathway during the osteogenic differentia-
tion process. In the present study, the ex-
pression of BMP-2 was investigated follow-
ing culture in osteogenic medium (contain-
ing 5.5 or 25 mM glucose) for seven days. 
Our data revealed that BMP-2 levels were 
increased in BMSCs cultured in osteogenic 
medium (containing 5.5 mM or 25 mM 
glucose) relative to the control. Additional-
ly, the BMP-2 concentration was lower in 
the BMSCs cultured under high-glucose 
osteogenic conditions compared to those 
ltured in normal glucose osteogenic condi-
tions (Figure 3A). 
 
Table 1: Primer sequences used in real-time RT-PCR 
Gene Forward primer Reverse primer 
RUNX2  5' GCGCATTCCTCATCCCAGTA3' 5'CTGGCTCAGATAGGAGGGGT3' 
ALP 5ATCGACGTGATCATGGGTGG3' 5'GGCCATCTAGCCTTGTACCC3' 
OCN 5'CGCTCTGTCTCTCTGACCTC3' 5'CGCCGGAGTCTGTTCACTAC3' 
GAPDH 5'CATCTTCCAGGAGCGAGACC3' 5'CTCGTGGTTCACACCCATCA3' 
 
 
Table 2: Flow cytometric analysis of cell cycles and proliferation indices between four groups  
(mean ± SE), proliferation index = (S + G2/M), (G0/G1 + S + G2/M) × 100 % 
Groups G0/G1(%) S(%) G2+M(%) Proliferation index(%) 
5.5 mM 63.19 ± 2.59 18.31 ± 1.63 18.50 ± 1.35 36.81 ± 2.59 
16.5 mM 58.42 ± 3.12 8.61 ± 0.75 32.98 ± 2.60 41.58 ± 3.12* 
25 mM 50.18 ± 3.80 19.12 ± 1.37 30.70 ± 3.07 49.82 ± 3.80* 
35 mM 68.25 ± 2.38 16.71 ± 1.08 15.04 ± 1.32 31.75 ± 2.30* 
The three high-glucose groups were significantly different from the control group (P < 0.05) 
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Figure 1: Different concentrations 
of high glucose had different ef-
fects on BMSC proliferation. 
A: High-glucose microenviron-
ments (16.5 and 25 mM) promoted 
BMSC proliferation. Another high-
glucose environment (35 mM) in-
hibited BMSC proliferation. Values 
are the mean ± SD for triplicate 
samples from a representative 
experiment. Student’s t-test was 
performed to determine statistical 
significance. *P < 0.05 
B, D: Flow cytometry analysis of 
the cell cycle showing that 25 mM 
glucose had the best effects on 
BMSC proliferation than the other 
three glucose concentrations. 
One-way ANOVA was performed 
to determine statistical signifi-
cance. *P < 0.05 
C, E: Annexin V-FITC conjugated 
to PI by flow cytometry showed 
that 35 mM glucose caused more 
significant cell apoptosis than the 
other three glucose concentra-
tions. One-way ANOVA was per-
formed to determine statistical sig-
nificance. *P < 0.05 
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Figure 2: High glucose had an inhibitory effect on BMSC osteogenic differentiation. 
A: BMSCs were cultured in four osteogenic media (glucose concentrations: 5.5 mM, 16.5 mM, 25 mM, 
and 35 mM, respectively) for 21 days; mineralized nodules were detected following Alizarin red S 
staining. Scale bars represent 100 µm. 
B: Graph illustrating the quantitative evaluation of Alizarin red S staining of the four groups. *P < 0.05 
vs. the normal/Diff group 
 
High glucose inhibited ALP activity and 
expression of RUNX2, ALP, and OCN 
To confirm the inhibition effects of high 
glucose on the osteogenic differentiation of 
BMSCs, we carried out ALP staining and 
ALP activity analysis. ALP staining re-
vealed the suppression effect of high glu-
cose on the osteogenic differentiation of 
BMSCs, and ALP activity analysis revealed 
that the ALP activity was 1.443, which was 
higher than that in the undifferentiated 
high-glucose group, but was decreased by 
1.39-fold compared to that in the differenti-
ated normal-glucose group (P < 0.01; Fig-
ure 3B). Furthermore, we extracted mRNA 
from the BMSCs cultured in both types of 
osteogenic medium for seven days, and per-
formed qRT-PCR to determine the expres-
sion levels of three osteoblast marker 
genes: RUNX2, a critical transcription fac-
tor for osteoblastic differentiation; ALP, an 
early osteoblast marker; and OCN, a mature 
osteoblast marker. In the differentiated 
high-glucose group, there was a 1.56, 1.48, 
and 1.55-fold decrease in the expression 
level of RUNX2, ALP, and OCN, respec-
tively (P < 0.01; Figure 3C). 
 
In vitro regulation of osteogenic differen-
tiation by the BMP pathway 
BMP-2 is known to positively regulate 
osteogenic differentiation. To verify wheth-
er treatment of BMSCs with BMP-2 can 
promote osteogenic differentiation and res-
cue the osteogenic suppression of high glu-
cose, we tested the intracellular BMP-2 lev-
els and RUNX2, ALP, and OCN expression 
in the BMSCs after treatment with ectogen-
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ic BMP-2. The intracellular BMP-2 in both 
osteogenic groups (5.5 mM and 25 mM 
glucose) was significantly elevated (Figure 
4A). The expression of RUNX2, ALP, and 
OCN was also increased by 1.72, 1.47, and 
1.47-fold in BMP-2–treated BMSCs cul-
tured in osteogenic medium containing 5.5 
mM glucose. And in BMSCs cultured in 
osteogenic medium containing 25 mM glu-
cose, the expression of these three osteo-
blastic genes was increased by 1.70, 1.53, 
and 1.48-fold, respectively (P < 0.05; Fig-
ure 4B), which was consistent with increase 
of BMP-2. Taken together, our results sug-
gest that the BMP pathway plays an im-
portant role in regulating the osteogenic dif-
ferentiation of BMSCs in a high-glucose 
environment. 
 
 
 
Figure 3: BMP signaling pathway in BMSCs was inhibited in high-glucose microenvironment. 
A: BMP-2 levels were tested after BMSCs were grown in normal or high-glucose osteogenic medium 
for seven days. β-actin was used as an internal control. 
B: Scanned images of ALP staining of BMSC after 7-d culture in osteogenic medium containing nor-
mal (5.5 mM) or high glucose (25 mM). Graph depicts the quantitative evaluation of ALP activity. The 
results represent the mean ± SD. *P < 0.05 vs. the normal/Diff group, n = 3 
C: Real-time PCR analysis of RUNX2, ALP, and OCN expression in normal and high-glucose condi-
tions grown in basal (Undiff) or osteogenic medium (Diff) for 7 d. The expression levels were normal-
ized to that of β-actin. The results represent the mean ± SD from three independent experiments per-
formed in triplicate. *P < 0.05 vs. the normal/Diff group 
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Figure 4: Up-regulated expression levels of RUNX2 by BMP-2 promoted BMSC osteogenic differenti-
ation in normal (5.5 mM) and high-glucose (25 mM) conditions. 
A: The level of endogenic BMP-2 in BMSCs grown in basal osteogenic medium containing normal (5.5 
mM) or high glucose (25 mM), or in the absence or presence of BMP-2 (100 ng/mL) for 7 d were 
measured by Western blot. 
B: Real-time PCR analysis of RUNX2, ALP, and OCN expression in BMSCs after 7-d culture in basal 
medium (Undiff) and osteogenic medium (Diff), containing normal (5.5 mM) or high glucose (25 mM) in 
the absence or presence of 100 ng/mL BMP-2. β-Actin was used as a control for equal loading. Re-
sults represent the mean ± SD from three independent experiments performed in triplicate. *P < 0.05 
vs. the normal /Diff groups 
 
 
DISCUSSION 
Diabetes is a common metabolic disor-
der characterized by hyperglycemia due to 
impaired insulin secretion, insufficient insu-
lin action, or both (King, 2008). A complex 
syndrome with more than one cause, diabe-
tes is responsible for numerous complica-
tions affecting the whole body. Compared 
to individuals without diabetes, patients 
with diabetes are more susceptible to perio-
dontal disease, which is recognized as the 
sixth most common complication of diabe-
tes (Dakovic and Pavlovic, 2008; Javed et 
al., 2007). Moreover, moderate to severe 
alveolar bone loss is more prevalent in dia-
betes mellitus patients (Al-Emadi et al., 
2006). Implant treatment is an attractive 
alternative to traditional fixed/removable 
prostheses (Levin et al., 2007, 2006). How-
ever, individuals with poorly controlled di-
abetes are more susceptible to developing 
complications after implant therapy than 
individuals with well-controlled diabetes 
(Fiorellini et al., 2000). The treatment of 
diabetes focuses on the attainment of opti-
mal glycemic control to prevent complica-
tions.  
The prevailing literature accounts for 
both the detrimental and beneficial effects 
of high glucose on MSCs, which is perplex-
ing. Previously, we found that high glucose 
affected the biological function of rat osteo-
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blasts (Ma et al., 2011). The potential of 
MSCs in tissue regeneration is gaining in-
creasing attention. Therefore, we focused 
on the biological function of stem cells in 
high-glucose conditions. Our initial assays 
determined that different concentrations of 
high glucose affected the biological func-
tion of BMSCs differently. In good agree-
ment with an earlier observation in MC3T3 
cells (Balint et al., 2001) and in telomerase-
immortalized MSCs (Li et al., 2007), we 
found that high glucose (< 25 mM) greatly 
promoted proliferation. However, if the 
glucose concentration was too high 
(35 mM), it would significantly suppress 
proliferation and induce cell apoptosis, 
which would be harmful to tissue regenera-
tion. Our findings were the opposite of the 
data obtained in rats. In rat MSCs, the re-
duction of glucose stimulated cell prolifera-
tion, and high glucose enhanced apoptosis 
(Stolzing et al., 2006). The discrepancy 
may be due to differences in the experi-
mental protocols and cell lines used, and 
further studies are necessary to investigate 
the difference. 
The osteogenic differentiation of mes-
enchymal stromal/stem cells is precisely 
regulated by signaling molecules and tran-
scription factors. Other physical factors 
such as inflammation and biomechanics 
also influence bone formation (Liu et al., 
2011). As a physical factor, the effects of 
high glucose on osteogenesis have also 
been extensively studied (Li et al., 2007; 
Wang et al., 2010). Our mineral test de-
monstrated that high glucose (16.5, 25, 
35 mM) inhibited the osteogenic differenti-
ation of BMSCs dose-dependently. Our da-
ta are in accord with that of some previous 
studies. For example, Hyun Kim et al. 
(2006) found that the mineralized nodule 
formation of periodontal ligament (PDL) 
cells in high glucose was lower than that in 
normal glucose medium. Gopalakrishnan et 
al. (2006) found that ALP activity, the num-
ber of nodules formed, and the area stained 
for collagen in BMSCs were greatly re-
duced in a high-glucose environment. 
Hyperglycemia has been thought to be a 
potential contributor to diabetic osteoporo-
sis (Schwartz, 2003), but the mechanism of 
bone loss is still unclear. To differentiate 
into mature osteoblasts, BMSCs undergo a 
series of differentiation stages, such as pro-
liferation, matrix development, and matrix 
mineralization. The transition from prolif-
eration to the matrix differentiation stage is 
characterized by the up-regulation of genes 
associated with matrix development and 
maturation, with that of the genes for colla-
gen and ALP occurring the earliest. How-
ever, proliferation slows down with the ex-
pression of osteoblast-specific markers. 
There is a reciprocal correlation between 
BMSC proliferation and differentiation 
(Pittenger et al., 1999). Our findings were 
in accordance with these conclusions. In 
our study, high glucose (16.5 and 25 mM) 
promoted proliferation but inhibited osteo-
genic differentiation. High glucose proba-
bly provides sufficient nutrients to BMSCs, 
thus promoting the energy metabolism of 
BMSCs, but the mechanism still requires 
exploration.  
We focused on the mechanism of high 
glucose on the osteogenic differentiation of 
BMSCs. We used 25 mM glucose as our 
test group to compare with the control 
group (5.5 mM). A member of the trans-
forming growth factor-b (TGF-b) super 
family, BMP-2 is a key signaling factor for 
inducing the differentiation of stem cells 
into osteoblasts (Yamaguchi et al., 2000). 
Therefore, we investigated the level of 
BMP-2 by western blot analysis. The ex-
pression of RUNX2, an important osteogen-
ic transcription factor, ALP, and OCN, two 
key osteogenic markers, was quantified by 
real-time PCR.  
Osteogenic differentiation of BMSCs is 
precisely regulated by signaling pathways 
and transcription factors. In particular, the 
modulation of the molecular differentiation 
into bone in MSCs by the BMP signaling 
pathway is well known. The importance of 
this precise regulation of BMP signaling 
and receptor binding is reflected in the ap-
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pearance of developmental disorders and 
dysfunctions in humans, such as bone and 
cartilage diseases (Thomas et al., 1997, 
1996) or cancer, in which specific compo-
nents of the BMP pathway are defective 
(Hartung et al., 2006). BMPs are multifunc-
tional growth factors that play very im-
portant roles in the BMP signaling pathway, 
and have been identified based on their abi-
lity to initiate ectopic bone formation in 
adult animals (Wozney et al., 1988). BMPs 
also play critical roles during embryonic 
development (Wills et al., 2006). Among 
them, BMP-2 is one of the most effective 
inducers of osteogenic differentiation 
(Cheng et al., 2003). Runx2 (also called 
Cbfa1), is a transcription factor required for 
osteoblastogenesis. Ducy et al. (1997) re-
ported that Runx2 binds the OCN promoter 
and is expressed in osteochondral progeni-
tors as well as in the early stages of osteo-
blastic differentiation. The forced expres-
sion of Runx2 in non-osteoblastic fibro-
blasts was sufficient to induce the expres-
sion of osteoblastic markers such as type I 
collagen, bone sialoprotein, OCN, and os-
teopontin. Moreover, Runx2-knockout mice 
exhibited no intramembranous or endo-
chondral ossification (Komori et al., 1997; 
Otto et al., 1997). Runx2 thus serves as an 
essential regulator of bone formation by 
osteoblasts and is at the intersection of 
many signaling pathways regulating osteo-
blast differentiation. While both BMP sig-
naling and Runx2 expression have been 
implicated in the expression of an osteo-
blast phenotype, the precise relationship 
between BMPs, Runx2 expression, and the 
transcription of osteoblast-related genes is 
still being studied. It has been reported 
BMP-2 could regulate the activity of Runx2 
and one of the BMP-Smad target genes is 
RUNX2 (Derynck and Zhang, 2003). In the 
present study, our data revealed that BMP-2 
levels and Runx2 expression were increased 
in BMSCs cultured in osteogenic medium 
containing 5.5 mM and 25 mM glucose rel-
ative to the control. This implies that the 
BMP signaling pathway plays an important 
role in the osteogenic differentiation of 
mouse BMSCs and that Runx2 was actually 
activated in this process. Additionally, we 
found that under high glucose (25 mM) os-
teogenic conditions, the BMP-2 concentra-
tion in the BMSCs was decreased, and the 
Runx2 expression was decreased simulta-
neously, which indicated another perspec-
tive to the relationship between BMP-2 and 
Runx2. Recent work from several groups 
has clarified that ectogenic BMP-2 could be 
used to promote the osteogenic differentia-
tion of MSCs (Koch et al., 2005; Pountos et 
al., 2010; Turgeman et al., 2002). There-
fore, we hypothesized that treatment with 
BMP-2 enhances the osteogenic activity of 
BMSCs under high-glucose conditions. Our 
data showed that the osteogenic differentia-
tion of BMSCs was improved through sup-
plementation with BMP-2 in a high-glucose 
environment. It could be inferred that the 
inhibition effects of high glucose could be 
reversed by addition ectogenic BMP-2.  
In summary, we have demonstrated that 
glucose in the microenvironment markedly 
affects gene regulation, proliferation, and 
differentiation, as well as the apoptosis of 
stem cells. According to our current anal-
yses, the high-glucose environment actually 
affected BMP-2 activation in the BMSCs 
during the osteogenic differentiation pro-
cess. BMP signaling pathway could en-
hance the bone regeneration of BMSCs 
through the activation of Runx2. This work 
provides a new insight into the effects of 
high glucose on the osteogenic differentia-
tion of mouse BMSCs. However, the com-
plex mechanism of the interaction between 
high glucose and osteogenic differentiation 
of BMSCs still requires further investiga-
tion. 
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